Compounds > pexiganan
Page last updated: 2024-10-15

pexiganan

Cross-References

ID SourceID
PubMed CID16132253
CHEMBL ID1275802
SCHEMBL ID476400
MeSH IDM0354729

Synonyms (14)

Synonym
l-lysinamide, glycyl-l-isoleucylglycyl-l-lysyl-l-phenylalanyl-l-leucyl-l-lysyl-l-lysyl-l-alanyl-l-lysyl-l-lysyl-l-phenylalanylglycyl-l-lysyl-l-alanyl-l-phenylaalanyl-l-valyl-l-lysyl-l-isoleucyl-l-leucyl-l-lysyl-
glycyl-l-isoleucylglycyl-l-lysyl-l-phenylalanyl-l-leucyl-l-lysyl-l-lysyl-l-alanyl-l-lysyl-l-lysyl-l-phenylalanylglycyl-l-lysyl-l-alanyl-l-phenylalanyl-l-valyl-l-lysyl-l-isoleucyl-l-leucyl-l-lysyl-l-lysinamide
147664-63-9
unii-tvf29q70q1
pexiganan [inn]
magainin i, 7-l-lysine-8-l-lysine-10-l-lysine-18-l-lysine-19-de-l-glutamic acid-21-l-leucine-23-l-lysinamide
tvf29q70q1 ,
pexiganan ,
CHEMBL1275802
SCHEMBL476400
gly-ile-gly-lys-phe-leu-lys-lys-ala-lys-lys-phe-gly-lys-ala-phe-val-lys-ile-leu-lys-lys-nh2
7-l-lysine-8-l-lysine-10-l-lysine-18-l-lysine-19-de-l-glutamic acid-21-l-leucine-23-l-lysinamide magainin i
pexiganan [mi]
EX-A7466

Compound-Compound Interactions

Pexiganan, a 22-residue magainin analog, alone and combined with betalactmas antibiotics in three experimental rat models of Gram-negative septic shock.

ExcerptReference
"To investigate the efficacy of pexiganan, a 22-residue magainin analog, alone and combined with betalactmas antibiotics in three experimental rat models of Gram-negative septic shock."( Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock.
Cirioni, O; D'Amato, G; Ghiselli, R; Giacometti, A; Kamysz, W; Mocchegiani, F; Orlando, F; Rocchi, M; Saba, V; Scalise, G; Silvestri, C; Łukasiak, J, 2005)
" In this study, we assessed the in vitro activity of MSI-78 alone and in combination with eight clinically used antimicrobial agents against several strains of Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli isolated from blood of neutropenic febrile patients."( In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.
Cirioni, O; D'Amato, G; Giacometti, A; Kamysz, W; Licci, A; Lukasiak, J; Nadolski, P; Riva, A; Scalise, G; Silvestri, C, 2005)

Dosage Studied

ExcerptReference
"5% at the dosage of 200 microg/ml."( Structure-function relationship of king cobra cathelicidin.
Lee, WH; Liu, XD; Shen, JH; Yu, GY; Zhang, Y; Zhao, H, 2010)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID592086Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 18 hrs by microbroth dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Synthetic mimics of antimicrobial peptides from triaryl scaffolds.
AID1075553Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 51559 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID692605Antimicrobial activity against Candida albicans ATCC 10231 after 48 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID1368708Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID1368703Antibacterial activity against Bacillus subtilis then incubated at 37 degC for 24 hrs by broth dilution assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID692602Antimicrobial activity against Escherichia coli JM109 after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID692604Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID1199318Antimicrobial activity against methicillin resistant Staphylococcus aureus DM21455 by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1227250Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 16 hrs2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Helical Antimicrobial Sulfono-γ-AApeptides.
AID1075554Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID534543Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 by radial diffusion assay incubated with matrix metalloprotease 7 for 5 mins2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1368706Induction of hemolysis in Sprague-Dawley rat erythrocytes at 200 uM incubated at 37 degC for 60 mins by spectrophotometry2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID1368705Induction of hemolysis in Sprague-Dawley rat erythrocytes incubated at 37 degC for 60 mins by spectrophotometry2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID1199324Selectivity index, ratio of HC50 for induction of hemolysis in New Zealand white rabbit RBC to MIC for Staphylococcus aureus DM214552015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID692583Toxicity in RBC assessed as hemolysis2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID534530Antimicrobial activity against multidrug-resistant Pseudomonas aeruginosa CCARM 2161 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID592085Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by microbroth dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Synthetic mimics of antimicrobial peptides from triaryl scaffolds.
AID534528Antimicrobial activity against vancomycin-resistant Enterococcus faecium CCARM 5028 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1199305Potency shift index, ratio of MIC for methicillin resistant Staphylococcus aureus DM21455 in presence of 4% BSA to MIC for methicillin resistant Staphylococcus aureus DM21455 in absence of 4% BSA2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1199319Antimicrobial activity against methicillin resistant Staphylococcus aureus DM09809R by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID534536Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 by colony count assay incubated with trypsin for 20 mins2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1227254Antimicrobial activity against Escherichia ATCC 25922 after 16 hrs2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Helical Antimicrobial Sulfono-γ-AApeptides.
AID1199304Antimicrobial activity against methicillin resistant Staphylococcus aureus DM21455 in presence of 4% BSA by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1075548Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID534527Antimicrobial activity against Micrococcus luteus KCTC 9341 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID692586Antimicrobial activity against Vancomycin-resistant Enterococcus faecalis ATCC 700802 after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID1227255Induction of hemolysis in human RBCs incubated for 1 hr2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Helical Antimicrobial Sulfono-γ-AApeptides.
AID1199303Antimicrobial activity against methicillin resistant Staphylococcus aureus DM21455 in absence of 4% BSA by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1075550Retention time of the compound by HPLC analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID534545Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 by radial diffusion assay incubated with Staphylococcus aureus Culture supernatant for 1 hr2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1075547Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID534537Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 by colony count assay incubated with trypsin for 1 hr2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1689762Antibacterial activity against Enterococcus faecium ATCC 135562 by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189Simple amphiphilic α-hydrazido acids: Rational design, synthesis, and in vitro bioactivity profile of a novel class of potential antimicrobial compounds.
AID534526Antimicrobial activity against Bacillus subtilis KCTC 2213 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID534525Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1368702Antibacterial activity against Escherichia coli then incubated at 37 degC for 24 hrs by broth dilution assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID1368704Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID1199325Selectivity index, ratio of HC50 for induction of hemolysis in New Zealand white rabbit RBC to MIC for Staphylococcus aureus DM09809R2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1199326Selectivity index, ratio of HC50 for induction of hemolysis in New Zealand white rabbit RBC to MIC for Bacillus cereus ATCC 117782015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID592087Toxicity in human RBC assessed as hemolysis after 1 hr2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Synthetic mimics of antimicrobial peptides from triaryl scaffolds.
AID692603Antimicrobial activity against Klebsiella pneumoniae ATCC 13383 after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID534533Antimicrobial activity against Citrobacter freundii KCTC 2359 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1199306Antimicrobial activity against Staphylococcus aureus ATCC 29213 in absence of 4% BSA by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1689763Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189Simple amphiphilic α-hydrazido acids: Rational design, synthesis, and in vitro bioactivity profile of a novel class of potential antimicrobial compounds.
AID534544Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 by radial diffusion assay incubated with Pseudomonas aeruginosa Culture supernatant for 1 hr2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1199320Antimicrobial activity against Bacillus cereus ATCC 11778 by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1227251Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis RP62A after 16 hrs2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Helical Antimicrobial Sulfono-γ-AApeptides.
AID534532Antimicrobial activity against Klebsiella oxytoca KCTC 1686 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID692584Antimicrobial activity against Bacillus subtilis BR151 after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID1199307Antimicrobial activity against Staphylococcus aureus ATCC 29213 in presence of 4% BSA by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1199321Induction of hemolysis in New Zealand white rabbit RBC after 1 hr2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID592084Antibacterial activity against Staphylococcus aureus ATCC 27660 after 18 hrs by microbroth dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Synthetic mimics of antimicrobial peptides from triaryl scaffolds.
AID1199323Selectivity index, ratio of HC50 for induction of hemolysis in New Zealand white rabbit RBC to MIC for Staphylococcus aureus DM40012015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID534534Antimicrobial activity against Salmonella enterica KCTC 2930 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1199317Antimicrobial activity against Staphylococcus aureus DM4001 by broth macrodilution method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1075552Antibacterial activity against beta-lactam-resistant Klebsiella pneumoniae ATCC 700603 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID1689764Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method2020European journal of medicinal chemistry, Mar-01, Volume: 189Simple amphiphilic α-hydrazido acids: Rational design, synthesis, and in vitro bioactivity profile of a novel class of potential antimicrobial compounds.
AID1227253Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 16 hrs2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Helical Antimicrobial Sulfono-γ-AApeptides.
AID1368707Cytotoxicity against human LNCAP cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids.
AID692585Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID534535Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 by colony count assay incubated with trypsin for 10 mins2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID692587Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis RP62A after 24 hrs by by broth micro-dilution method2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Lipidated peptidomimetics with improved antimicrobial activity.
AID1075551Hemolytic activity in human erythrocytes after 1 hr by spectrophotometric analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID1075549Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
AID1689765Hemolytic activity in human RBC2020European journal of medicinal chemistry, Mar-01, Volume: 189Simple amphiphilic α-hydrazido acids: Rational design, synthesis, and in vitro bioactivity profile of a novel class of potential antimicrobial compounds.
AID1227252Antimicrobial activity against Enterococcus faecalis ATCC 700802 after 16 hrs2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Helical Antimicrobial Sulfono-γ-AApeptides.
AID534529Antimicrobial activity against Listeria monocytogenes KCTC 19111 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1418828Antibacterial activity against Micrococcus luteus after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Simplified lipid II-binding antimicrobial peptides: Design, synthesis and antimicrobial activity of bioconjugates of nisin rings A and B with pore-forming peptides.
AID534531Antimicrobial activity against Escherichia coli KCTC 1039 after 18 hrs by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1199308Potency shift index, ratio of MIC for Staphylococcus aureus ATCC 29213 in presence of 4% BSA to MIC for Staphylococcus aureus ATCC 29213 in absence of 4% BSA2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID1075546Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth microdilution assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Small molecular antibacterial peptoid mimics: the simpler the better!
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (9.33)18.2507
2000's19 (25.33)29.6817
2010's39 (52.00)24.3611
2020's10 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.33%)5.53%
Reviews4 (5.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers[NCT01594762]Phase 3200 participants (Actual)Interventional2014-06-30Completed
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers[NCT01590758]Phase 3189 participants (Actual)Interventional2014-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01590758 (3) [back to overview]Number of Participants With Clinical Response
NCT01590758 (3) [back to overview]Number of Participants With Microbiological Success
NCT01590758 (3) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAE)
NCT01594762 (3) [back to overview]Number of Participants With Clinical Response
NCT01594762 (3) [back to overview]Number of Participants With Microbiological Response
NCT01594762 (3) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAE)

Number of Participants With Clinical Response

The numbers of participants with Clinical Response, defined as resolution of infection, are reported. (NCT01590758)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Topical Pexiganan Cream 0.8%43
Topical Placebo Control63

[back to top]

Number of Participants With Microbiological Success

The numbers of participants with Microbiological Response, defined as eradication of all initial pathogens, are reported. (NCT01590758)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Topical Pexiganan Cream 0.8%16
Topical Placebo Control28

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAE)

The numbers of participants with TEAEs, including those with Serious TEAEs, are reported (NCT01590758)
Timeframe: 28 days

,
InterventionParticipants (Count of Participants)
Incidence of any TEAEIncidence of Serious TEAE
Topical Pexiganan Cream 0.8%269
Topical Placebo Control253

[back to top]

Number of Participants With Clinical Response

The numbers of participants with Clinical Response, defined as resolution of infection, are reported. (NCT01594762)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Topical Pexiganan Cream 0.8%56
Topical Placebo Control54

[back to top]

Number of Participants With Microbiological Response

The numbers of participants with Microbiological Response, defined are eradication of all baseline pathogens, are reported. (NCT01594762)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Topical Pexiganan Cream 0.8%18
Topical Placebo Control27

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAE)

The number of participants with TEAEs, including Serious TEAEs, are reported (NCT01594762)
Timeframe: 28 days

,
InterventionParticipants (Count of Participants)
Incidence of any TEAEIncidence of Serious TEAE
Topical Pexiganan Cream 0.8%258
Topical Placebo Control212

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pqq cofactor
PQQ Cofactor: A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES.. pyrroloquinoline quinone : A pyrroloquinoline having oxo groups at the 4- and 5-positions and carboxy groups at the 2-, 7- and 9-positions.		2.0610orthoquinones;
pyrroloquinoline cofactor;
tricarboxylic acid		anti-inflammatory agent;
antioxidant;
cofactor;
water-soluble vitamin (role)
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		2.2510pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.2510nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.1110fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		6.95433-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.1110N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.1710kanamycinsbacterial metabolite
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		2.2510penicillin allergen;
penicillin		antibacterial drug
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		3.1310beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		2.110arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
deoxycytidine
[no description available]		2.2510pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2,6-dichloroindophenol
2,6-Dichloroindophenol: A dye used as a reagent in the determination of vitamin C.. 2,6-dichloroindophenol : A quinone imine that is indophenol substituted by chloro groups at positions 2 and 6.. N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine : 1,4-benzoquinone imine having a 3,5-dichloro-4-hydroxyphenyl substituent attached to the nitrogen atom.		2.0610dichlorobenzene;
quinone imine
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.5120glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		3.0340dihydrogen
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.0510diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
fluorides
[no description available]		2.0510halide anion;
monoatomic fluorine
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		2.1310alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.4220penicillin allergen;
penicillin		antibacterial drug
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		2.1310cephalosporinantibacterial drug
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.2510organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
1,2-dipalmitoyl-3-phosphatidylethanolamine
1,2-dipalmitoyl-3-phosphatidylethanolamine: RN given refers to parent cpd without isomeric designation		2.0110
azauracil
azauracil: minor descriptor (64-72); major descriptor (73-86); on line search URACIL (66-74); URACIL/AA (75-86); INDEX MEDICUS search URACIL (64-72); AZAURACIL (73-86). 6-azauracil : A 1,2,4-triazine compound having oxo-substituents at the 3- and 5-positions.		2.25101,2,4-triazines;
nucleobase analogue		antimetabolite
gentamicin c1a
[no description available]		2.2510gentamycin C
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.4520beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sulbactam
[no description available]		3.1310penicillanic acids
beta-lactams
2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.		2.0210beta-lactam antibiotic allergen;
beta-lactam
fengycin
fengycin: lipopeptide from Bacillus subtilis		2.4110cyclodepsipeptide
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		2.25102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
mangostin
mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.		2.1110aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
1-palmitoyl-2-oleoylphosphatidylethanolamine
1-palmitoyl-2-oleoylphosphatidylethanolamine: RN given refers to (Z)-isomer; RN for cpd without isomeric designation not available 12/88. 1-palmitoyl-2-oleoyl phosphatidylethanolamine : A phosphatidylethanolamine in which the phosphatidyl acyl groups at C-1 and C-2 are palmitoyl and oleoyl respectively.		2.0110(18R,21S)-24-amino-21-hydroxy-21-oxido-15-oxo-16,20,22-trioxa-21lambdalambda(5)-phosphatetracosan-18-yl icosanoate;
phosphatidylethanolamine
dimyristoylphosphatidylcholine
1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).		2.74301,2-diacyl-sn-glycero-3-phosphocholine;
phosphatidylcholine 28:0;
tetradecanoate ester		antigen;
mouse metabolite
ceftriaxone
[no description available]		2.05101,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
ceftazidime
[no description available]		2.0510cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
aztreonam
[no description available]		2.0510beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
1-palmitoyl-2-oleoylphosphatidylcholine
1-palmitoyl-2-oleoylphosphatidylcholine: RN given refers to (Z)-isomer		2.4220
cholanic acid
cholanic acid: RN given refers to parent cpd without isomer designation. cholanic acid : A steroid acid that consists of cholane having a carboxy group in place of the methyl group at position 24.. colanic acid : A polyanionic heteropolysaccharide containing a repeat unit with D-glucose, L-fucose, D-galactose, and D-glucuronic acid sugars that are non-stoichiometrically decorated with O-acetyl and pyruvate side-chains		2.3110cholanic acids
melitten
Melitten: Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes.		2.4920
tachyplesin peptide, tachypleus tridentatus
tachyplesin peptide, Tachypleus tridentatus: isolated from the hemocytes of the horseshoe crab (Tachypleus tridentatus); cationic peptide; 17 amino acid residues given in first source		2.4420
magainin 2 peptide, xenopus
magainin 2 peptide, Xenopus: from skin of Xenopus laevis; 23-amino acid sequence given in first source; differs from magainin 1 by substitution of Lys instead of Gly at position 10 & Asn instead of Lys at position 22; also used to prevent development of malarial oocysts in mosquito vector; Z-12 is magainin 2 with Lys and Phe residues replaced with their respective D-isomers; homologue of the Xenopus laevis cement; GenBank AF004262 (mouse), AF007791, AF038451-2 (human)		4.0240
cecropin p1-li
cecropin P1-LI: antibacterial peptide isolated from porcine intestine; has immunoreactivity in epithelial cells of duodenum & glucagon cells of the pancreas		1.9910
dermaseptin s
dermaseptin: 34 amino acid residues given in first source; antimicrobial peptide of amphibian skin		2.0210
protegrin-5
protegrin-5: GenBank X84096		1.9910
protegrin-1
protegrin-1: GenBank X84094		2.4220
magainin 1 peptide, xenopus
magainin I: Antibiotic peptide. Thought to preferentially bind to anionic phosholipids.		3.0810
ly-146032
[no description available]		2.1110heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
ropocamptide
ropocamptide: from granulocytes & keratinocytes, precursor to cathelicidins; MW 16-18 kDa; GenBank AJ224927 (eCATH-1). cathelicidin : A group of small, cationic polypeptides (consisting of 12-97 amino acids) that are found in humans and other species, including farm animals (E.g. cattle, horses, pigs, sheep etc). They show a broad spectrum of antimicrobial activity against bacteria, enveloped viruses and fungi.		2.0510
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		2.8220glycoside
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.42201,2-diacyl-sn-glycero-3-phosphocholine
colistin
Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.		7.4620
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.2510
tigecycline
[no description available]		7.1710
clavanin a
clavanin A: histidine-rich, amidated, alpha-helical protein isolated from the hemocytes of Styela clava; amino acid sequence in first source		1.9910
acetylcellulose
acetylcellulose: coating compound. cellulose acetate : A glucan derivative obtained through the esterification of cellulose by acetic anhydride or acetic acid, resulting in the substitution of some of the hydroxy groups of cellulose by acetyl groups. It is used in a variety of applications including base material for photographic film, clothing, membrane filters, coatings, food packaging, and as a frame material for eyeglasses.		2.4110
ConditionIndicatedRelationship StrengthStudiesTrials
Extravascular Hemolysis
[description not available]		03.3560
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		03.3560
Bacterial Infections, Gram-Positive
[description not available]		02.5220
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		02.5220
Gastric Diseases
[description not available]		02.2110
Infections, Helicobacter
[description not available]		02.5520
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.5520
C gattii Infection
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6120
Cerebromeningitis
[description not available]		02.2510
Cryptococcosis
Fungal infection caused by genus CRYPTOCOCCUS.		02.2510
Blood Poisoning
[description not available]		02.7730
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.7730
Diabetic Feet
[description not available]		011.5159
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		011.5159
Bacterial Infections, Gram-Negative
[description not available]		02.1110
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		02.1110
Bacterial Disease
[description not available]		09.84119
Bacterial Infections
Infections by bacteria, general or unspecified.		09.84119
Infections, Staphylococcal
[description not available]		02.0710
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.0710
E coli Infections
[description not available]		02.4220
Primary Peritonitis
[description not available]		02.0210
Endotoxin Shock
[description not available]		02.4220
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.4220
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		02.0210
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		02.4220
Hydrophobia
[description not available]		02.0210
Infection, Wound
[description not available]		02.0210
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		02.0210
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		02.0210
Infection
[description not available]		02.9110
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		14.9110
Ulcer
A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.		0710